Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

v3.24.3
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
3 Months Ended
Sep. 30, 2024
Notes Tables  
Schedule of restructuring charges

In the first quarter of fiscal 2025, the Company announced enterprise-wide restructuring focused on recovering operating margins and optimizing our manufacturing footprint. The Company is expecting to incur costs related to these actions through fiscal 2026, which will be recorded when specified criteria are met. The restructuring and restructuring-related charges for periods presented were recorded in the Consolidated Statements of Earnings as follows (in thousands):

Quarter Ended

September 30, 

2024

Cost of sales

$

4,898

Selling, general and administrative(1)

5,371

Total

$

10,269

(1) Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs.

Restructuring and restructuring-related costs by segment are as follows (in thousands):

Three months ended September 30, 2024

Employee

Asset-related

severance

and other

Total

Protein Sciences

$

2,274

$

7,417

$

9,691

Diagnostics and Spatial Biology

444

444

Corporate

134

134

Total

$

2,852

$

7,417

$

10,269

The following table summarizes the changes in the Company’s accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands):

Employee

Asset

    

severance(1)

    

impairment and other(2)

    

Total

Expense incurred in the first quarter of 2025

$

2,852

$

7,417

$

10,269

Cash payments

(189)

(189)

Non-cash adjustments

(7,417)

(7,417)

Accrued restructuring actions balance as of September 30, 2024

$

2,663

$

$

2,663

(1) Relates to impacted employees’ final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or relocation of certain manufacturing sites.

(2) Primarily relates to impairment of intangibles and inventory as a result of the closure and relocation of certain manufacturing sites.

The restructuring and restructuring-related charges, including the impairment of assets held-for-sale, for periods presented were recorded in the Consolidated Statements of Earnings as follows (in thousands):

Quarter Ended

September 30, 

2024

Cost of sales

$

Selling, general and administrative(1)

753

Total

$

753

(1) Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs.

Restructuring and restructuring-related costs by segment are as follows (in thousands):

Three months ended September 30, 2024

Employee

Asset-related

severance

and other

Total

Protein Sciences

$

14

$

40

$

54

Diagnostics and Spatial Biology

Corporate

(3)

702

699

Total

$

11

$

742

$

753

The following table summarizes the changes in the Company’s accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands):

Employee

Asset-related

Impairment of

severance(1)

and other(2)

assets held-for-sale

Total

Expense incurred in the second quarter of 2024

4,882

504

6,038

11,424

Incremental expense incurred in the third quarter of 2024

133

1,140

1,273

Incremental expense incurred in the fourth quarter of 2024

409

4,737

15,926

21,072

Cash payments

(4,882)

(2,800)

(7,682)

Non-cash adjustments

(3,391)

(21,963)

(25,354)

Adjustments(3)

219

219

Accrued restructuring actions balance as of June 30, 2024

$

761

$

190

$

$

952

Incremental expense incurred in the first quarter of 2025

753

753

Cash payments

(412)

(775)

(1,187)

Accrued restructuring actions balance as of September 30, 2024

$

349

$

169

$

$

518

(1) Relates to impacted employees’ final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or sale of certain distribution and manufacturing sites.

(2) Primarily relates to impairment of right-of-use-assets, lease termination fees, consulting fees, and expenses for changes to supporting IT systems that are enabling the Company to complete the restructuring initiatives.

(3) Relates to the refinement of the accrual recorded in the second quarter of fiscal 2024.

Protein Sciences  
Notes Tables  
Schedule of restructuring charges Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):

Employee

severance

Accrued restructuring actions balance as of June 30, 2023

$

897

Fiscal year 2024 cash payments

(1,118)

First quarter fiscal year 2024 adjustments(1)

89

Second quarter fiscal year 2024 adjustments(1)

132

Accrued restructuring actions balance as of June 30, 2024

$

(1) Fiscal year 2024 adjustments relate to the refinement of the accrual recorded in fiscal year 2023.